Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14777810 | 0.85 | HCRTR1 (0.53) | KMT2AALDH1A1HTTKDM4ELMNA | |
| SCHEMBL16087429 | 0.76 | TDP1 (0.48) | KMT2AALDH1A1HTTLMNAGAA | |
| SCHEMBL28304921 | 0.74 | ALDH1A1 (0.56) | KMT2AALDH1A1HTTKDM4ELMNA | |
| SCHEMBL14778174 | 0.73 | GAA (0.54) | KMT2AALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL13373241 | 0.71 | L3MBTL1 (0.62) | KMT2AALDH1A1HTTKDM4ELMNA | |
| SCHEMBL14777731 | 0.70 | KMT2A (0.55) | KMT2AALDH1A1HTTKDM4ELMNA | |
| SCHEMBL1429869 | 0.70 | KMT2A (0.58) | KMT2AALDH1A1HTTKDM4ELMNA | |
| SCHEMBL14778164 | 0.70 | PKLR (0.51) | KMT2AALDH1A1HTTKDM4ELMNA | |
| SCHEMBL4164590 | 0.68 | HTT (0.54) | KMT2AALDH1A1HTTKDM4ELMNA | |
| SCHEMBL3321806 | 0.68 | POLB (0.45) | KMT2AALDH1A1KDM4ELMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920073-B2 | Compositions useful for inhibiting HIV-1 infection and methods using same | DREXEL UNIVERSITY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214998-A1 | NOVEL COMPOSITIONS USEFUL FOR INHIBITING HIV-1 INFECTION AND METHODS USING SAME | CCL5, CCR5, CXCL10 | KMT2A 3223/4885ALDH1A1 1735/4885HTT 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.